ZBIO FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and prospectus (collectively, the 'Registration Statement') issued in connection with Zenas BioPharma's September 2024 initial public offering ('IPO' or the 'Offering'), of the important June 16, 2025 lead plaintiff deadline in the securities class action first filed by the firm.
SO WHAT: If you purchased Zenas BioPharma securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Zenas BioPharma class action, go to https://rosenlegal.com/submit-form/?case_id=37109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 16, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, the Registration Statement contained false and/or misleading statements and/or failed to disclose that: (1) Zenas BioPharma materially overstated the amount of time it would be able to fund its operations using existing cash and expected net proceeds from the IPO; and (2) as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Zenas BioPharma action, go to https://rosenlegal.com/submit-form/?case_id=37109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
NASA IV&V in Fairmont faces drastic funding cut
Jul. 5—dbeard @ MORGANTOWN — NASA's Katherine Johnson Independent Verification & Validation Facility in Fairmont could see a drastic budget cut under President Trump's Fiscal Year 2026 Discretionary Budget Request. But members of West Virginia's Congressional delegation are working to prevent it As part of an overall proposed NASA budget cut, Johnson IV &V would see its funding fall from its current $43.3 million (from FY 2024) to $13.8 million in FY 2026 — just one third of the current budget. NASA is working on answers to questions from The Dominion Post about the ramifications of the cut and will provide those next week. In its 2026 Budget Technical Supplement, the agency says, "In FY 2026, NASA plans to significantly reduce and restructure both the NASA Engineering and Safety Center and Independent Verification and Validation program as part of the effort to consolidate the overall Agency Technical Authority program. In FY 2026, NASA will allocate $9.9 million for IV &V to ensure the program can provide software assurance support to the future Moon to Mars programs." The Dominion Post reached out to Sens. Shelley Moore Capito and Jim Justice, and Rep. Riley Moore for comments on the proposal. Capito spokeswoman Kelley Moore (no relation) said Capito "is aware of the proposed cuts to NASA that would impact the mission and the facility at Katherine Johnson IV &V." She has been in contact with leadership at the facility, Goddard Space Flight Center, which oversees the work at IV &V, and NASA Headquarters. "It has also been conveyed to NASA and to the Senate Appropriations Committee that Sen. Capito will oppose any cuts to this facility that would impact workforce or its mission, " Moore said. Moore noted that since NASA does not have an administrator or a nominee at this time, there has not been a budget hearing where this topic could be raised. "Regardless, Sen. Capito is working hard to protect this facility that she so proudly helped name around this time in 2019." Justice did not respond to several requests for comment. Moore said, "I am closely tracking the proposed cuts to NASA's Fairmont facility. I have been in constant communication with the appropriations subcommittee chairman who oversees its funding, and will use my position on the Appropriations Committee to fight for the important work being done there." Here's a breakdown of the numbers that factor into IV &V's budget — with several layers of authority above IV &V. IV &V overall falls under NASA's Safety, Security and Mission Services. That budget was cut from $3.131 billion in FY 2024 to $3.092 billion in FY 2025 and will fall to $2.118 billion in FY 2026 the federal fiscal year begins Oct. 1). Under SS &MS, is Engineering Safety & Operations. Its budget will fall from $1.088 billion in FY 2024 to $620.3million in FY 2026 and $446.5 million in FY 2027. And under ES &O, the Agency Technical Authority funding will fall from $196.1 million in FY 2024 to $69.6 million in FY 2026. "The Agency Technical Authority program protects the health and safety of NASA's workforce by evaluating programs, projects, and operations to ensure safe and successful completion. ATA capabilities provide expert technical excellence, mission assurance, and technical authority agency wide." IV &V falls directly under the Agency Technical Authority, with funding from several accounts. Funding from the Safety, Security and Mission Services account will be cut from $39.2 million to $9.9 million — for software assurance support for Moon and Mars programs, as mentioned above. Funding from the Exploration account will go from $3.3 million to $2 million. Funding from the Space Operations account will go from $800, 000 to $700, 000. One account source will see an increase: Science account funding will go from $0 in FY 2024 to $1.2 million for FY 2026. A footnote hints at some flexibility: "The IV &V program will work with Mission Directorate to adjust FY 2026 allocations as the FY 2026 operating plan is developed." Some information provided to The Dominion Post noted that cuts to IV &V have been proposed in the past, but not to this extent.
Wall Street Journal
an hour ago
- Wall Street Journal
Investors Come Around to Trump's Uncertainty
Uncertainty is usually the enemy of investment. This year not so much. Twin uncertainties about tariffs and whether President Trump will honor U.S. security guarantees have prompted governments and companies to pour money into defending themselves, helping stocks. For now.
Associated Press
an hour ago
- Associated Press
FIFA cuts ticket price to $13.40 for Club World Cup semifinal between Chelsea and Fluminense
EAST RUTHERFORD, N.J. (AP) — FIFA cut standard ticket prices for the semifinal between Chelsea and Fluminense at MetLife Stadium in East Rutherford, New Jersey, on Tuesday to $13.40 from $473.90 earlier in the past week. FIFA has used dynamic pricing for the 63-game tournament. Standard ticket prices for Wednesday's semifinal between European champion Paris Saint-Germain and Real Madrid in New Jersey start at $199.60. FIFA had dropped ticket prices to $11.15 for a quarterfinal in Orlando, Florida, between Fluminense and Al Hilal. and in Philadelphia between Chelsea and Palmeiras. The dramatic drop in prices was first reported by The Athletic. Many matches during the tournament have had sparse crowds. Real Madrid has been an exception, drawing at least 60,000 for all five of its matches, including 76,611 for its quarterfinal win Saturday over Borussia Dortmund in New Jersey. ___ AP soccer:
